Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View

Sumitomo Pharma Co., Ltd.

https://www.sumitomo-pharma.com/

Latest From Sumitomo Pharma Co., Ltd.

Lucid Diagnostics Seeks Clear Path To US Reimbursement For Esophageal Precancer Test

Bookmark
  • Interviews
By Ashley Yeo

Lishan Aklog, CEO of New York-based Lucid Diagnostics, has a long-term vision to provide the paradigm of prevention-to-treatment care for esophageal cancer. In the short term, the company anticipates a favorable outcome from an upcoming pivotal Medicare assessment of its early screening technology.

Innovation Cancer

Q2 Korean Biotech Roundup: Partners Return Multiple Assets

Bookmark
  • News
By Jung Won Shin

The second quarter in South Korea was marked by the return of several assets by licensing partners, including Thea Open Innovation, which gave back rights to two ophthalmic programs in-licensed from OliX. Merck & Co. also cancelled a co-research deal with Artiva Biotherapeutics.

South Korea Deals

Finance Watch: Earnings Season Brings Job Cuts, Even At Big Pharma

Bookmark
  • Analysis
By Mandy Jackson

Restructuring Edition: Even big pharma companies are not immune from workforce reductions. BMS and Sanofi joined that ranks of Evotec, CureVac and BenevolentAI in cutting jobs. Also, Vaxxinity will de-list and Hepion winds down its NASH trial, among other strategic updates.

Restructuring Business Strategies

How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies

Bookmark
  • Interviews
By Barnaby Pickering

UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.

Companies Deals
See All

Company Information

  • Industry
  • Distributors
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Adagio Pharmaceuticals Ltd.
    • Altavant Sciences
    • Boston Biomedical, Inc.
    • Boston Biomedical Pharma, Inc.
    • Cannasat Therapeutics Inc.
    • Cynapsus Therapeutics, Inc.
    • Dainippon Sumitomo Pharma Co., Ltd.
    • Dainippon Sumitomo Pharma Europe Ltd.
    • DS Pharma Promo Co., Ltd,
    • Elevation Pharmaceuticals, Inc.
    • Enzyvant Therapeutics, Inc.
    • Enzyvant Sciences, Ltd.
    • Myovant Sciences Ltd
    • Myovant Sciences GmbH
    • Myovant Sciences, Inc.
    • Oryx Pharmaceuticals Inc.
    • SB Bioscience Co., Ltd.
    • Spirovant Sciences
    • Sumitomo Chemical Co., Ltd.
    • Sumitomo Dainippon Pharma America, Inc. (formerly Dainippon Sumitomo Pharma America Holdings, Inc.)
    • Sumitomo Dainippon Pharma Oncology, Inc.
    • Sumitomo Pharmaceuticals America
    • Sumitomo Pharmaceuticals (Suzhou) Co., Ltd.
    • Sumitovant Biopharma
    • Sunovion Pharmaceuticals Inc. (formerly Sepracor Inc.)
    • Sunovion Pharmaceuticals Europe Ltd.
    • Sunovion Respiratory Development Inc.
    • Tolero Pharmaceuticals, Inc.
    • Urovant Sciences, Inc.
    • Sumitomo Pharmaceuticals Taiwan Co., Ltd.
    • Sumitomo Dainippon Pharma Co., Ltd.
UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By